Fresh analysis backs sotagliflozin as treatment to reduce heart failure deaths

23 August 2021

Texas, USA-based Lexicon Pharmaceuticals (Nasdaq: LXRX) today presented additional analyses of sotagliflozin data from the SOLOIST and SCORED Phase III clinical trials at ESC Congress 2021 - The Digital Experience.

Sotagliflozin is a first-in-class, investigational dual SGLT1 and SGLT2 inhibitor that showed substantial reductions, compared to placebo, in the primary endpoint of total cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure in both studies in patients with type 2 diabetes and worsening heart failure or chronic kidney disease.

Lexicon originally out-licensed sotagliflozin to Sanofi (Euronext: SAN) in 2015 for global (ex-Japan) rights, in a deal that provided an upfront $300 million to the US firm plus potential sales milestone payments of up to $1.4 billion from the diabetes drug, trade named Zynquista in Europe, where it was approved in 2019. However, Sanofi pulled out of the deal in 2019 and, after an initial dispute, paid a termination fee of $260 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK